课题基金 / 基金详情

131 IODINE RADIOLABELED ANTI B1 MONOCLONAL ANTIBODY IN B CELL LYMPHOMA

131 IODINE RADIOLABELED ANTI B1 MONOCLONAL ANTIBODY IN B CELL LYMPHOMA
131 B 细胞淋巴瘤中的碘放射性标记抗 B1 单克隆抗体
批准号：
6274061
负责人：
MANSOOR N SALEH
金额：
$2.59万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-01-26 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6274061
关键词：
B cell lymphoma B lymphocyte clinical research human subject human therapy evaluation iodine monoclonal antibody neoplasm /cancer immunotherapy neoplasm /cancer radionuclide therapy neoplastic transformation nonHodgkin's lymphoma radiation dosage

项目摘要

项目成果

MANSOOR N SALEH的其他基金

相似基金

相关文献

中文摘要
翻译
这是I-131标记的放射性抗B1的II期试验 用于治疗低度恶性淋巴瘤的单抗以及 转化的淋巴瘤。先前治疗失败的患者通常不会 有大量的选择，通常有较差的总体结果。这个 放射性标记抗-B1的I期试验证明了 提供85cGy全身辐射，具有适度的可逆毒性 与难治性低血压患者的显著反应相关 恶性淋巴瘤。目前的研究着眼于85cgy全身的剂量。 难治性低度淋巴瘤或转化性淋巴瘤的放射治疗。
英文摘要
This is a phase II trial of the I-131 labeled radioactive anti-B1 monoclonal antibody for the treatment of low grade lymphoma, as well as transformed lymphoma. Patients who failed prior therapy generally do not have substantial options, and in general have por overall outcome. The phase I trial of the radiolabeled anti-B1 demonstrated the ability to deliver 85 cGy whole body radiation with modest reversible toxicity and was associated with significant responses in patients with refractory low grade lymphoma. The current study looks at the dose of 85 cGy whole body radiotherapy in refractory low grade lymphoma or transformed lymphoma.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
海外基金